NCR1 and glioblastoma: Consistent with our earlier findings in CC-treated GBM mice [7], we observed a significant influx of activated (NKp46+, tumoricidal) NK cells in STO-1-treated tumors (Figure 8A,B), with fewer NK cells in Pac-treated tumors.